Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 244 Melanoma 141 Squamous Cell Carcinoma of Head and Neck 139 Parkinson Disease 4, Autosomal Dominant Lewy Body 119 Neoplasm Metastasis 104 Triple Negative Breast Neoplasms 96 Neoplasms 91 Lung Neoplasms 91 Breast Neoplasms 81 Colorectal Neoplasms 70 Carcinoma, Renal Cell 69 Head and Neck Neoplasms 59 Urinary Bladder Neoplasms 50 Stomach Neoplasms 47 Ovarian Neoplasms 46 Endometrial Neoplasms 46 Carcinoma, Transitional Cell 44 Carcinoma, Hepatocellular 35 Uterine Cervical Neoplasms 34 Pancreatic Neoplasms 34 Esophageal Neoplasms 27 Prostatic Neoplasms 26 Recurrence 25 Carcinoma, Squamous Cell 25 Carcinoma 25 Sarcoma 24 Brain Neoplasms 24 Glioblastoma 23 Hodgkin Disease 19 Cholangiocarcinoma 19

Interventions

enfortumab vedotin 2 pembrolizumab 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Bladder Cancer × pembrolizumab × 1 year × Clear all

NCT07346053 2026-01-16

Chrono-EVP

British Columbia Cancer Agency

Phase 3 Not yet recruiting

Advanced Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡